BioTech

Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the day at $7.69. Traded volume was 13,801,124 million shares in the last session and the average volume of the stock remained 27.14 million shares. The beta of the stock remained 1.49. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Pfizer Inc. (NYSE:PFE) has consistently paid out dividends, even during the financial crisis, making it a solid dividend stock to look at. Pfizer Inc. (NYSE:PFE) rose 0.09 percent to $32.42 yesterday on volume of 24.17 million shares. The intra-day range of the stock was $32.24 to $32.62. Pfizer Inc. (NYSE:PFE) has a market capitalization of $207.46 million.

Gilead Science, Inc. (NASDAQ:GILD)which is the top drug maker for Hepatitis and HIV treatments, is developing novel cancer drugs. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on Mar 11, 2014 reported a decrease of -0.49% to the closing price of $79.84. Its fifty two weeks range is $43.78 -$84.88. The total market capitalization recorded $122.81 billion. The overall volume in the last trading session was 10,568,469 million shares. In its share capital, Gilead Sciences, Inc. (NASDAQ:GILD) has 1.53 million outstanding shares.

Novavax Inc. (NASDAQ:NVAX) reported a net loss of $14.1 million, or $0.07 per share, for the fourth quarter of 2013, compared to a net loss of $8.0 million, or $0.06 per share, for the fourth quarter of 2012. On Tuesday, shares of Novavax, Inc. (NASDAQ:NVAX) advanced 0.68% to close the day at $5.90. Company return on investment (ROI) is -36.40% and its monthly performance is recorded as 10.49%. Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is 39.48%.